Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION: Anakinra for persistent respiratory symptoms post-acute COVID-19
2023-508123-12-00Phase 3Authorised
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Nov 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in post-COVID syndrome comparing 8 weeks anakinra with 4 weeks anakinra + 4 weeks placebo (2 arms). Primary endpoint: Primary composite PACS improvement score. Planned start Nov 2023; status: authorised.
02
Drugs
anakinra
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2023-508123-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508123-12-00.